AUTEN-67

Edit links
From Wikipedia, the free encyclopedia
AUTEN-67
Clinical data
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
  • N-[3-(1H-Benzimidazol-1-yl)-1,4-dioxo-1,4-dihydro-2-naphthalenyl]-4-nitrobenzenesulfonamide[1]
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H14N4O6S
Molar mass474.45 g·mol−1
3D model (JSmol)
  • c1ccc2c(c1)C(=O)C(=C(C2=O)n3cnc4c3cccc4)NS(=O)(=O)c5ccc(cc5)[N+](=O)[O-]
  • InChI=1S/C23H14N4O6S/c28-22-16-5-1-2-6-17(16)23(29)21(26-13-24-18-7-3-4-8-19(18)26)20(22)25-34(32,33)15-11-9-14(10-12-15)27(30)31/h1-13,25H
  • Key:FSAINSJUQREKEK-UHFFFAOYSA-N

AUTEN-67 is an autophagy-enhancing drug candidate that increases autophagic flux in cell lines and in vivo models.[1]

It hampers the progression of neurodegenerative symptoms in a Drosophila model of Huntington's disease.[2] It is developed by Velgene Biotechnology Ltd.

References[edit]

  1. ^ a b Papp D, Kovács T, Billes V, Varga M, Tarnóci A, Hackler L, et al. (2016). "AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects". Autophagy. 12 (2): 273–86. doi:10.1080/15548627.2015.1082023. PMC 4835959. PMID 26312549.
  2. ^ Billes V, Kovács T, Hotzi B, Manzéger A, Tagscherer K, Komlós M, et al. (May 2016). "AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington's Disease". Journal of Huntington's Disease. 5 (2): 133–47. doi:10.3233/JHD-150180. PMID 27163946.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=AUTEN-67&oldid=1108859505"